Alterity Therapeutics Valuation
| ATHE Stock | USD 5.00 0.39 8.46% |
At this time, the firm appears to be undervalued. Alterity Therapeutics shows a prevailing Real Value of $6.22 per share. The current price of the firm is $5.0. Our model approximates the value of Alterity Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.56, shares outstanding of 14.8 M, and Operating Margin of (4.70) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Alterity Therapeutics' valuation include:
Price Book 14.5737 | Enterprise Value | Enterprise Value Ebitda 0.7546 | Price Sales 23.2415 | Enterprise Value Revenue 113.9898 |
Undervalued
Today
Please note that Alterity Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Alterity Therapeutics is based on 3 months time horizon. Increasing Alterity Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Alterity stock is determined by what a typical buyer is willing to pay for full or partial control of Alterity Therapeutics. Since Alterity Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Alterity Stock. However, Alterity Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.0 | Real 6.22 | Target 11.0 | Hype 5.01 | Naive 5.53 |
The real value of Alterity Stock, also known as its intrinsic value, is the underlying worth of Alterity Therapeutics Company, which is reflected in its stock price. It is based on Alterity Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Alterity Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Alterity Therapeutics helps investors to forecast how Alterity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Alterity Therapeutics more accurately as focusing exclusively on Alterity Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Alterity Therapeutics' intrinsic value based on its ongoing forecasts of Alterity Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Alterity Therapeutics' closest peers. If more than one evaluation category is relevant for Alterity Therapeutics we suggest using both methods to arrive at a better estimate.
Alterity Therapeutics Cash |
|
Alterity Valuation Trend
Comparing Alterity Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Alterity Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Alterity Therapeutics Total Value Analysis
Alterity Therapeutics is presently forecasted to have valuation of 83.68 M with market capitalization of 86.56 M, debt of 159.04 K, and cash on hands of 34.81 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Alterity Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
83.68 M | 86.56 M | 159.04 K | 34.81 M |
Alterity Therapeutics Investor Information
The company recorded a loss per share of 2.22. Alterity Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 9th of January 2023. Based on the key indicators related to Alterity Therapeutics' liquidity, profitability, solvency, and operating efficiency, Alterity Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Alterity Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Alterity Therapeutics has an asset utilization ratio of 20.91 percent. This indicates that the Company is making $0.21 for each dollar of assets. An increasing asset utilization means that Alterity Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Alterity Therapeutics Ownership Allocation
The market capitalization of Alterity Therapeutics is $86.56 Million. Almost 98.4 percent of Alterity Therapeutics outstanding shares are held by general public with 1.6 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Alterity Therapeutics Profitability Analysis
The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.54 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Alterity Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Alterity Therapeutics and how it compares across the competition.
About Alterity Therapeutics Valuation
The stock valuation mechanism determines Alterity Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Alterity Therapeutics. We calculate exposure to Alterity Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Alterity Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.4 M | 4.6 M | |
| Pretax Profit Margin | (5.46) | (5.73) | |
| Operating Profit Margin | (5.61) | (5.89) | |
| Net Loss | (5.47) | (5.75) | |
| Gross Profit Margin | 1.09 | 1.03 |
Alterity Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Alterity Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.1 M |
Alterity Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Alterity Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Alterity we look at many different elements of the entity such as Alterity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Alterity Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Alterity Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Alterity Therapeutics' worth.Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |